<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-048651</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Renal transplantation in HIV-infected patients in Spain</dc:title>
<dc:description xml:lang="en">HIV infection has experienced dramatic improvement in morbidity and mortalitywith the highly active antiretroviral therapy (HAART). This prompted a reevaluation of organ-solid transplantation as a treatment option for HIV-infected patients.Some trials in the United States have shown that one- and 2-year graft andpatient survival is comparable to HIV-negative transplant population. In Europe theexperience is still scarce. The aim of this study is to analyse the outcome and theclinical characteristics of HIV-infected patients who received kidney transplantationin Spain in the HAART era. Ten patients were transplanted in our countrysince 2001. Only one patient was black. The main cause of end-stage renal diseasereported was glomerulonephritis. Six of the recipients were coinfected by hepatitisC virus. Inclusion criteria included undetectable HIV viral load and CD4counts greater than 200/&amp;#956;L. Immunosuppression consisted of steroids, tacrolimusand mycophenolate mofetil, with antibody induction in 4 cases. The median andmean follow-up was 11 and 16.3+15.6 (3-46) months, respectively. One recipientlost his graft because of early renal venous thrombosis. The remaining patients arefunctioning graft with mean serum creatinina level of 1.5 + 0.5 mg/dl. Biopsy-provenacute rejection was diagnosed in 4 recipients and was reversed in all caseswith antirejection treatment. The plasma HIV RNA levels have remained controlledand CD4 counts have been stable in excess of 200 cell/&amp;#956;L. None of patientshave developed AIDS complications. Recipients receiving protease inhibitor-basedHAART regimens required significant dosing modification to maintain appropriatetacrolimus levels. Our results show that renal transplantation can be a safe andeffective treatment in select HIV-infected patients. Like other series, the acute rejectionrate was higher than in non-HIV recipients. The reasons of this rejectionincidence remain unknown</dc:description>
<dc:creator>González-Molina, M</dc:creator>
<dc:creator>Mazuecos, A</dc:creator>
<dc:creator>Pascual, J</dc:creator>
<dc:creator>Oppenheimer, F</dc:creator>
<dc:creator>Marcén, R</dc:creator>
<dc:creator>Baltar, J. M</dc:creator>
<dc:creator>Puig-Hooper, C. E</dc:creator>
<dc:creator>Sola, E</dc:creator>
<dc:creator>Cofán, F</dc:creator>
<dc:creator>López, F</dc:creator>
<dc:creator>Gómez, E</dc:creator>
<dc:creator>Rivero, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El pronóstico de la infección VIH ha mejorado de forma espectacular con elempleo de la terapia antirretroviral de gran actividad (TARGA). Esto ha llevado aconsiderar el trasplante de órgano sólido como una alternativa terapéutica en estospacientes. La experiencia en Estados Unidos ha puesto de manifiesto que la supervivenciaa medio plazo del trasplante renal es similar a la observada en pacientesno infectados. En Europa se han comunicado sólo casos aislados. El objetivode este estudio ha sido analizar la evolución de los pacientes con infecciónVIH que han recibido trasplante renal en nuestro país en la era TARGA. Desde elaño 2001 se han realizado en España 10 trasplantes renales. Seis de ellos presentancoinfección por el virus de la hepatitis C. Los criterios de selección incluíancarga viral del VIH indetectable y recuento de linfocitos CD4 &gt; 200 cél/&amp;#956;L. Unpaciente sufrió precozmente trombosis de la vena renal realizándose trasplantectomía.Los restantes receptores mantienen el injerto renal funcionante con creatininaplasmática de 1,5 ± 0,5 mg/dl, tras 11 ± 15,6 (3-46) meses de seguimiento.Cuatro pacientes desarrollaron rechazo agudo con buena respuesta altratamiento. No hemos observado progresión de la infección VIH manteniéndosela carga viral controlada y la cifra de linfocitos CD4 superior a 200 cél/&amp;#956;L. En los4 casos tratados con inhibidores de la proteasa se produjo una marcada interaccióncon tacrolimus que obligó a disminuir la dosis del inmunosupresor y/o modificarel TARGA. Nuestros resultados muestran que el trasplante renal puede serun tratamiento eficaz y seguro en pacientes con infección VIH adecuadamenteseleccionados. Como en otras series, hemos observado una alta tasa de rechazoagudo cuyas causas no son aún conocidas</dc:description>
<dc:source>Nefrologia;26(1): 113-120, ene. 2006. tab</dc:source>
<dc:identifier>ibc-048651</dc:identifier>
<dc:title xml:lang="es">Trasplante renal en pacientes con infección VIH en España</dc:title>
<dc:subject>^d24718^s22012</dc:subject>
<dc:subject>^d32319</dc:subject>
<dc:subject>^d30103</dc:subject>
<dc:subject>^d30696</dc:subject>
<dc:subject>^d28625</dc:subject>
<dc:subject>^d6235</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29475^s22083</dc:subject>
<dc:subject>^d4409</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d35395</dc:subject>
<dc:subject>^d33123</dc:subject>
<dc:subject>^d28628</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d50497^s22009</dc:subject>
<dc:type>article</dc:type>
<dc:date>200601</dc:date>
</metadata>
</record>
</ibecs-document>
